Want to join the conversation?
In Oct. 2015, $BMY and $FPRX entered into an exclusive worldwide licensing and collaboration agreement for the development and commercialization of $FPRX's colony stimulating factor 1 receptor (CSF1R) antibody program. In consideration for licensing rights, $BMY will make an upfront payment of $350MM, which will be included in R&D expense.
$AAL is giving pay hikes to its employees but investors are sulking.
Unicorn Frappuccino. The latest hit from $SBUX. Can't wait to see how this will affect its results.
At what point should $AMZN consider a stock split? $1000 per share seems pretty high.